Core Insights - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology to combat cancer [1][5] - The company will participate in the DealFlow Discovery Conference on January 28-29, 2026, where CEO Robert Bitterman will present and the management team will hold one-on-one investor meetings [2][3][4] Company Overview - Phio Pharmaceuticals is advancing its INTASYL® gene silencing technology, which aims to enhance the immune system's ability to target and kill cancer cells [5] - The lead clinical program, PH-762, targets the PD-1 gene associated with various skin cancers and is currently in a Phase 1b trial evaluating its efficacy against cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [5] Event Details - The DealFlow Discovery Conference will take place at the Borgata Hotel in Atlantic City, NJ, on January 28-29, 2026 [9] - Investors can register for the conference at no cost to meet with the Phio Pharmaceuticals management team [4]